Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news


From To
J&J unit ends hepatitis C drug development in crowded market

Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.

11 September 2017
Generic PrEP in France and Scotland challenges access across the UK

The issue of drug procurement and pricing is complex but it is difficult to see how different patents should apply within Europe, and especially not within the UK.

08 September 2017
HIV i-Base
Did HIV Pharma “Pay to Delay” Generic Truvada?

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

04 September 2017
AIDS activists urge N.Y. attorney general to probe Gilead for antitrust violations

A group of prominent AIDS activists is urging the New York attorney general to investigate Gilead Sciences (GILD) for potential antitrust violations in connection with deals the drug maker struck with rivals that sought to sell generic versions of a best-selling HIV treatment.

30 August 2017
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds

An analysis of 440 people switched to generic antiretroviral drugs at an Italian clinic and a matched cohort of patients who remained on their branded medication has

24 August 2017
Roger Pebody
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff

Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs.

21 August 2017
Gilead's Newer Tenofovir Patents

The company may have found a way to protect its newest HIV franchise for longer than anticipated, perhaps 10 years longer than it suggests in its 10-K (see p. 15), in both the US and EU.

15 August 2017
Seeking Alpha
Mylan launches 3 HIV generics in Canada

Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).

11 August 2017
Drug Store News
AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

07 August 2017
Mylan to Provide Generic Truvada for U.K. Trial

The NHS confirmed Thursday that Mylan had won the drug procurement process for a three-year-long implementation trial for pre-exposure prophylaxis, or PrEP, which is used to prevent HIV infection.

03 August 2017
Wall Street Journal
← First12345...98Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.